Result: 61 - 77 of 77
DRAMP IDNAMEDescriptionMedical_useStage of developmentCompany
DRAMP18173Pediocin PA-1 (Bacteriocin)Pediococcus acidilactici UL5Gastrointestinal tract infections; Stomach and intestine infections (Murine model; In-vivo)PreclinicalUnknown
DRAMP18174Nisin A (Type A lantibiotic)Lactococcus lactis subspUrogenital tract infections; Spermicidal activity (Rabbit model; In-vivo) PreclinicalUnknown
DRAMP18175Bac8cSynthetic derivative of bactenecin from bovine neutrophilsStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18176Temporin10aFrog (Rana ornativentris) skinStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18177Syphaxin(SPX1-22)Frog (Leptodactylus syphax) skinStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18178IDR-1Derivative of bactenecin from bovine neutrophilsPrevention of infections in the immune compromisedPhase IUnknown
DRAMP18179IDR-1002Derivative of bactenecin from bovine neutrophilsStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP18180Buforin IIAsian Toad (Bufo bufo gargarizans) stomachStaphylococus aureusanti-infectivesPreclinicalUnknown
DRAMP20773Dusquetide(SGX942)an analog of Innate Defense Regulator (IDR)Treatment of Head and Neck CancerPhase III Soligenix
DRAMP20760C16G2a synthetic AMPTreatment of Adult and Adolescent Dental SubjectsPhase IIC3 Jian
DRAMP18181DP178 (T20, Enfuvirtide & Fuzeon)C-terminus of the ectodomain of gp41HIV-1 membrane fusion inhibitor;AIDSProved by FDATrimeris
DRAMP18182Sifuvirtide (SFT)designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformationHIV fusion inhibitor;AIDSPhase II Unknown
DRAMP18183SB006 (M6)tetra-branched multimeric form of the linear sequenceGram-negative infectionsPreclinicalSpiderBiotech
DRAMP20761LTX-109LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. Treatment of Nasal Carriers MRSAPhase I/IIaLytix Biopharma AS
DRAMP20774Murepavadin (POL7080)synthetic by amino acid substitution of protegrin I.Treatment of nosocomial pneumonia and ventilator-associated bacterial pneumonia (VABP)Phase III Polyphor Ltd.
DRAMP18160Omiganan (MBI-226/MX-226/CLS001)Synthetic 12-mer cationic peptide derived from indolicidinTreatment of atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, acne vulgaris, rosacea and facial seborrheic dermatitisPhase III(catheter-related infections,Failure), Phase III(rosacea, completed), Phase II(atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, and acne vulgaris, completed), Phase III(facial seborrheic dermatitis, recruiting)Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc.(developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)
DRAMP28983PL-5This product is a national category 1 anti-infective innovation category in China, and has obtained PCT US and Chinese invention patent authorizations. Suitable for skin and wound infections, especially for stubborn infectious diseases caused by drug-resistant bacteria, against traditional antibiotics, "super bacteria" Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Acinetobacter baumannii containing NDM-1 gene have very strong bactericidal advantages. Its preparation antimicrobial peptide PL-5 spray is the first antimicrobial peptide variety to enter clinical research in my country, and this product has also been supported by the National Health and Family Planning Commission’s 12th and 13th Five-Year "Major New Drug Development" projects. Phase I clinical research has been completed, and Phase II clinical research is currently underway.Skin wound infectionPhase IIChangchun Protelight Pharmaceutcial & Biotechnology Co Ltd
Close
Sign in     login

Forgot your password?